AbbVie Inc.
AbbVie Reports First-Quarter 2025 Financial Results and Key Business Updates
Summary
AbbVie Inc. reported its first-quarter 2025 financial results, showing net revenues of $13.343 billion, an 8.4% increase on a reported basis and 9.8% on an operational basis. Diluted EPS was $0.72 on a GAAP basis, reflecting an unfavorable impact of $0.13 per share related to acquired IPR&D and milestones expense. The company also announced strategic updates, including a new CEO appointment and marketing authorizations for key drugs. Press release and financial statements are furnished as exhibits.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement